Nanospheric Chemotherapeutic and Chemoprotective Agents
Abstract
The purpose of this research is to explore the ability of tyrosine-derived nanospheres to improve the anti-tumor activity while simultaneously targeting the drug-nanosphere complex to diseased cells thereby minimizing unwanted effects on healthy cells. This report describes the optimization of nanospheres binding efficiency of three anti-cancer agents: camptothecin paclitaxel and vitamin D3 Tyrosine-derived nanospheres efficiently encapsulate vitamin D3 and paclitaxel under all investigated conditions. However our nanospheres bind only limited amounts of camptothecin regardless of presence of Vitamin D3 and/or optimization of experimental conditions and fabrication technique. The optimum formulation for highest binding and stability of camptothecin vitamin D3 is DTO-SA/5K nanospheres. Preliminary In Vitro and In Vivo studies suggest that (a) tyrosine-derived nanospheres provide highly effective delivery of hydrophobic paclitaxel to human tumor cells in vitro; (b) tyrosine-derived nanospheres exhibit no toxicity as compared to CrEL; (c) Tyrosine-derived nanospheres containing paclitaxel exhibit anti-tumor activity in a breast cancer xenograft model that is similar to that of an equivalent dose and schedule of clinically used formulation of Cremophor-paclitaxel. In condusion we are confident that tyrosine-derived nanospheres offer the potential for effective parenteral delivery of a wide array of hydrophobic drugs without the cytotoxicity problems commonly exhibited by surfactant-based drug delivery systems.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2008
- Accession Number
- ADA493655
Entities
People
- Larisa Sheihet
Organizations
- Rutgers University–New Brunswick